RE:RE:RE:RE:RE:RE:The Comapny Performed, Management disappointed. I have to give credit to much of the research on Donnatal to another poster on another site. Donnatal was first made 90 years ago and the patent has long expired. In theory, anyone should be able to produce Donnatal as it is a relatively basic compound. The three expensive drugs that Donnatal competes twith - Libra, Xifaxen and Lotronex (not sure if I have spelled these correctly and I am time crunched to check), are all patented drugs (thats why they cost in the thousands for a 30 day supply). The innovation of Valeant, and to an extent Concordia, is that they found drugs like Donnatal (in Valeant's case Nitropress and Isuprel) that nobody except one generic company was bothering to manufacture anymore. Things such as this is not a concidence that explains why VRX and CXR have been trading in concern. The other poster on another site, and it is unfortunate that I can not remember their name, likens it to Tylenol (cheap now because lots of generics available). Concordia can sell Donnatal for 20 years at a few dollars a bottle (like Tylenol) or they can continue selling it for $797 a bottle for the next three years aggressively. This is what I believe they are doing. This is what is perceived as "Valeant-ish" even though Concordia has not itself taken 100X price increases. It appears from the timeline Donnatal price jumped in 2012, so this was before Concordia had it. However, its all about the perception to extract as much profit as possible from the marketplace before another generic similar to Donnatal brings competition to this significant segment.
quote=select1011]....hence why they are desperate to increase their Don sales force. The intimation that I got from the CC today was that the increased sales force was to expand the market/sales. To be honest, they said the investment would pay off, but they didn't commit to a timeline for how long.[/quote]